O-020Quality-of-life results from RAISE: randomized, double-blind phase III study of FOLFIRI plus ramucirumab or placebo in patients with metastatic colorectal carcinoma after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine

R. Garcia-Carbonero1, R. Obermannova2, G. Bodoky3, J. Prausova4, T.-E. Ciuleanu5, P. Garcia Alfonso6, D. Portnoy7, A. Cohn8, E. Van Cutsem9, K. Yamazaki10, S.-E. Al-Batran11, P. Rougier12, A. Liepa13, L. Yang14, Y. Zhang14, F. Nasroulah14, S.-C. Chang14, J. Tabernero15 Hospital Universitario Virgen del Rocío Instituto de Biomedicina de Sevilla (IBIS), Sevilla, Spain Comprehensive Cancer Care Department, Faculty of Medicine, Masaryk University, Brno, Czech Republic St László Teaching Hospital, Budapest, Hungary University Hospital Motol, Prague, Czech Republic Prof. Dr. I. Chiricuta Institute of Oncology, Napoca, Romania Hospital General Universitario Gregorio Marañón, Madrid, Spain West Clinic, Memphis, Tennessee, USA Rocky Mountain Cancer Center, Denver, Colorado, USA Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium Shizuoka Cancer Center, Nagaizumi, Japan Krankenhaus Nordwest, Frankfurt, Germany Hopital Europeen Georges Pompidou, Paris, France Eli Lilly and Company, Indianapolis, Indiana, USA Eli Lilly and Company, Bridgewater, New Jersey, USA Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona, Spain